Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Cirrhosis

Free Subscription Articles published in Gastroenterology Retrieve available abstracts of 66 articles: HTML format

Single Articles

June 2026
1. KIM GA, Jang H, Kim MY, Park JH, et al
   Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes.
   Gastroenterology. 2026;170:1571-1583.
   PubMed     Abstract available
   
   
   April 2026
2. TORP N, Johansen S, Jensen EL, Maagaard M, et al
   Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease.
   Gastroenterology. 2026;170:803-814.
   PubMed     Abstract available
   
   
   
3. LOOMBA R, Clark VC, Mandorfer M, Miravitlles M, et al
   Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.
   Gastroenterology. 2026;170:829-842.
   PubMed     Abstract available
   
   
   March 2026
4. SARIN SK, Tripathti DM, Lohse AW
   Non-cirrhotic Portal Fibrosis, Idiopathic Portal Hypertension and Porto-sinusoidal Vascular Diseases: From Debates to Future Directions.
   Gastroenterology. 2026 Mar 10:S0016-5085(26)00199.
   PubMed    
   
   
   
5. WANG M, Chen F, Gao J, Liu Q, et al
   Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis.
   Gastroenterology. 2026;170:569-583.
   PubMed     Abstract available
   
   
   February 2026
6. KATO S, Hikita H, Tsukamoto O, Sato K, et al
   Activation of the Integrin alphaV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy.
   Gastroenterology. 2026 Feb 27:S0016-5085(25)06526.
   PubMed     Abstract available
   
   
   
7. LUO J
   Machine Learning in Cirrhosis: Moving from Static Admission Risk to Dynamic Decision Support.
   Gastroenterology. 2026 Feb 11:S0016-5085(26)00121.
   PubMed    
   
   
   
8. TAKEFUJI Y
   Enhancing Inpatient Mortality Prognostication in Cirrhosis Patients Through Machine Learning Techniques.
   Gastroenterology. 2026 Feb 11:S0016-5085(26)00120.
   PubMed    
   
   
   
9. ACEITUNO L, Banares J, Pons M, Rivera-Esteban J, et al
   The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease.
   Gastroenterology. 2026;170:385-394.
   PubMed     Abstract available
   
   
   January 2026
10. HIRODE G, Zangneh HF, Cerocchi O, Khalili K, et al
    Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.
    Gastroenterology. 2026 Jan 20:S0016-5085(25)05993.
    PubMed     Abstract available
    
    
    November 2025
11. DENG ZL, Safaei N, Schutte SL, Ohlendorf V, et al
    High Prevalence and Local Dissemination of Daptomycin-Resistance Mutations for Enterococcus faecium in Cirrhotic Patients.
    Gastroenterology. 2025 Nov 19:S0016-5085(25)06045.
    PubMed    
    
    
    
12. KIM NJ, Li M, Vutien P, Mecham B, et al
    Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.
    Gastroenterology. 2025 Nov 14:S0016-5085(25)05906.
    PubMed     Abstract available
    
    
    October 2025
13. ORMAN ES, Fortune BE, John BV, Asrani SK, et al
    AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.
    Gastroenterology. 2025 Oct 20:S0016-5085(25)05959.
    PubMed     Abstract available
    
    
    September 2025
14. ROHM TV, Dos Reis FCG, Cunha E Rocha K, Isaac R, et al
    Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.
    Gastroenterology. 2025;169:691-704.
    PubMed     Abstract available
    
    
    August 2025
15. LOU TW, Ren TY, Fan JG
    An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair.
    Gastroenterology. 2025 Aug 21:S0016-5085(25)05901.
    PubMed    
    
    
    
16. LIU WY, Huang S, Ji H, Kim SU, et al
    From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective.
    Gastroenterology. 2025;169:326-336.
    PubMed     Abstract available
    
    
    July 2025
17. SILVEY S, Kamath PS, George J, Choudhury A, et al
    Enhancement of Inpatient Mortality Prognostication with Machine Learning in a Prospective Global Cohort of Patients with Cirrhosis with External Validation.
    Gastroenterology. 2025 Jul 18:S0016-5085(25)05770.
    PubMed     Abstract available
    
    
    
18. ACKERMANN O, Bernard O, Franchi-Abella S, Almes M, et al
    The natural history of gastroesophageal varices in children with portal hypertension.
    Gastroenterology. 2025 Jul 15:S0016-5085(25)05748.
    PubMed     Abstract available
    
    
    June 2025
19. BAJAJ JS, Shawcross DL, Choudhury A, Karvellas CJ, et al
    Defining Organ Failures in Patients with Cirrhosis: Consensus Statements.
    Gastroenterology. 2025 Jun 9:S0016-5085(25)00844.
    PubMed    
    
    
    
20. MCGETTIGAN B, Hernandez-Tejero M, Malhi H, Shah V, et al
    Immune Dysfunction and Infection Risk in Advanced Liver Disease.
    Gastroenterology. 2025;168:1085-1100.
    PubMed     Abstract available
    
    
    May 2025
21. JUANOLA A, Ma AT, Cullaro G, Alexander MP, et al
    DEVELOPMENT OF ACUTE KIDNEY INJURY IN A PATIENT WITH ALCOHOL-RELATED CIRRHOSIS: THE IMPORTANCE OF DIAGNOSING THE CAUSE OF AKI.
    Gastroenterology. 2025 May 19:S0016-5085(25)00764.
    PubMed    
    
    
    April 2025
22. LENS S
    Simvastatin and Rifaximin for Decompensated Cirrhosis: A Hope Unfulfilled.
    Gastroenterology. 2025 Apr 23:S0016-5085(25)00638.
    PubMed    
    
    
    
23. GUPTA V, Sehrawat TS, Pinzani M, Strazzabosco M, et al
    Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.
    Gastroenterology. 2025;168:675-690.
    PubMed     Abstract available
    
    
    March 2025
24. SILVEY S, Patel N, Khoruts A, Bajaj JS, et al
    Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts.
    Gastroenterology. 2025 Mar 21:S0016-5085(25)00535.
    PubMed    
    
    
    
25. KISSELEVA T, Ganguly S, Murad R, Wang A, et al
    Regulation of Hepatic Stellate Cell Phenotypes in MASH.
    Gastroenterology. 2025 Mar 20:S0016-5085(25)00528.
    PubMed     Abstract available
    
    
    February 2025
26. FROMME M, Payance A, Mandorfer M, Thorhauge KH, et al
    Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi *ZZ Genotype).
    Gastroenterology. 2025;168:367-381.
    PubMed     Abstract available
    
    
    January 2025
27. KUMAR N, Chaudhary A
    Comments on "Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program".
    Gastroenterology. 2025 Jan 30:S0016-5085(25)00326.
    PubMed    
    
    
    
28. RHEE H, Kim MJ, Kim DY, An C, et al
    Non-contrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance: A randomized, single-center trial.
    Gastroenterology. 2025 Jan 22:S0016-5085(25)00049.
    PubMed     Abstract available
    
    
    December 2024
29. DAVIS JPE, Lim JK, Francis FF, Ahn J, et al
    AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review.
    Gastroenterology. 2024 Dec 20:S0016-5085(24)05664.
    PubMed     Abstract available
    
    
    November 2024
30. FUJIWARA N, Lopez C, Marsh TL, Raman I, et al
    Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis.
    Gastroenterology. 2024 Nov 7:S0016-5085(24)05660.
    PubMed     Abstract available
    
    
    
31. DORNER H, Stolzer I, Mattner J, Kaminski S, et al
    Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease.
    Gastroenterology. 2024;167:1183-1197.
    PubMed     Abstract available
    
    
    October 2024
32. CLARK VC, Strange C, Strnad P, Sanchez AJ, et al
    Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).
    Gastroenterology. 2024;167:1008-1018.
    PubMed     Abstract available
    
    
    September 2024
33. MAK LY, Yuen MF
    Surveillance for hepatocellular carcinoma in cirrhosis: End of monopoly for serum alpha fetoprotein.
    Gastroenterology. 2024 Sep 28:S0016-5085(24)05533.
    PubMed    
    
    
    
34. MARSH TL, Parikh ND, Roberts LR, Schwartz ME, et al
    A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.
    Gastroenterology. 2024 Sep 16:S0016-5085(24)05460.
    PubMed     Abstract available
    
    
    August 2024
35. PREMKUMAR M, Dhiman RK, Duseja A, Mehtani R, et al
    Recompensation of Chronic Hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: Prospective Cohort study from an HCV elimination program.
    Gastroenterology. 2024 Aug 22:S0016-5085(24)05359.
    PubMed     Abstract available
    
    
    July 2024
36. VAN KLEEF LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, et al
    Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.
    Gastroenterology. 2024;167:357-367.
    PubMed     Abstract available
    
    
    June 2024
37. VENKATESWARAN N
    Seladelpar as an alternate second line agent for Primary Biliary Cirrhosis.
    Gastroenterology. 2024 Jun 20:S0016-5085(24)05064.
    PubMed    
    
    
    
38. ZHU CP, Liu SQ, Wang KQ, Xiong HL, et al
    Targeting 5-Hydroxytryptamine receptor 1A in portal vein to decrease portal hypertension.
    Gastroenterology. 2024 Jun 19:S0016-5085(24)05062.
    PubMed     Abstract available
    
    
    May 2024
39. HANSCOM M
    Magnetically guided capsule endoscopy comparable to EGD for detecting esophagogastric varices in patients with cirrhosis.
    Gastroenterology. 2024 May 28:S0016-5085(24)05001.
    PubMed    
    
    
    
40. WANG R, Li B, Huang B, Li Y, et al
    Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis.
    Gastroenterology. 2024 May 27:S0016-5085(24)04936.
    PubMed     Abstract available
    
    
    
41. HILSCHER MB, Wysokinski WE, Andrews JC, Simonetto DA, et al
    Portal Vein Thrombosis in the Setting of Cirrhosis: Evaluation and Management Strategies.
    Gastroenterology. 2024 May 25:S0016-5085(24)04951.
    PubMed    
    
    
    March 2024
42. GAO F, Seto WK, Zheng MH
    Preventing Overdiagnosis of Nonalcoholic Fatty Liver Disease: Established Cutoff Values for Transient Elastography Are Needed.
    Gastroenterology. 2024;166:541-542.
    PubMed    
    
    
    
43. AN T, Liu L, Li X
    Factors Associated With the Influence of Liver Fibrosis Should Be Fully Considered.
    Gastroenterology. 2024;166:540-541.
    PubMed    
    
    
    February 2024
44. WONG RJ, Yang Z, Cheung R, Singal AK, et al
    Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among U.S. Veterans with Steatotic Liver Disease.
    Gastroenterology. 2024 Feb 28:S0016-5085(24)00238.
    PubMed     Abstract available
    
    
    
45. LENS S
    In Search of the Best Second-Line Therapy for Primary Biliary Cholangitis.
    Gastroenterology. 2024 Feb 20:S0016-5085(24)00185.
    PubMed    
    
    
    
46. TRIVEDI PJ, Hirschfield GM, Adams DH, Vierling JM, et al
    Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts.
    Gastroenterology. 2024 Feb 9:S0016-5085(24)00165.
    PubMed     Abstract available
    
    
    January 2024
47. POSE E, Piano S, Juanola A, Gines P, et al
    HEPATORENAL SYNDROME IN CIRRHOSIS.
    Gastroenterology. 2024 Jan 19:S0016-5085(24)00054.
    PubMed     Abstract available
    
    
    
48. LAURIDSEN MM, Gronkjaer LL, Khraibut S, Patel N, et al
    The multi-dimensional challenge of poor oral health in cirrhosis - disparities and solutions.
    Gastroenterology. 2024 Jan 13:S0016-5085(24)00043.
    PubMed    
    
    
    November 2023
49. GARCIA-TSAO G, Abraldes JG, Rich NE, Wong VW, et al
    AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Gastroenterology. 2023 Nov 17:S0016-5085(23)05143.
    PubMed     Abstract available
    
    
    October 2023
50. AMPUERO J, Berzigotti A
    Prognostication in Advanced Chronic Liver Disease Using Liver Stiffness Measurement: Repetita Iuvant.
    Gastroenterology. 2023;165:829-831.
    PubMed    
    
    
    
51. SEMMLER G, Yang Z, Fritz L, Kock F, et al
    Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
    Gastroenterology. 2023;165:1041-1052.
    PubMed     Abstract available
    
    
    
52. MAN S, Deng Y, Ma Y, Fu J, et al
    Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China.
    Gastroenterology. 2023;165:1025-1040.
    PubMed     Abstract available
    
    
    
53. WATTACHERIL JJ, Abdelmalek MF, Lim JK, Sanyal AJ, et al
    AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Gastroenterology. 2023;165:1080-1088.
    PubMed     Abstract available
    
    
    September 2023
54. XIE L, Guo H
    Question on the use of BMI >/= 25 kg/m(2) to define obesity to analyze the incidence and risk factors of hepatic steatosis and hepatic fibrosis in the Chinese population.
    Gastroenterology. 2023 Sep 8:S0016-5085(23)04983.
    PubMed    
    
    
    
55. WANG Y, Huang Y, Chase RC, Li T, et al
    Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019.
    Gastroenterology. 2023;165:773-783.
    PubMed     Abstract available
    
    
    
56. INTAGLIATA NM, Rahimi RS, Higuera-de-la-Tijera F, Simonetto DA, et al
    Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study.
    Gastroenterology. 2023;165:717-732.
    PubMed     Abstract available
    
    
    
57. ZUO T, Xie Q, Liu J, Yang J, et al
    Macrophage-Derived Cathepsin S Remodels the Extracellular Matrix to Promote Liver Fibrogenesis.
    Gastroenterology. 2023;165:746-761.
    PubMed     Abstract available
    
    
    August 2023
58. HUANG DQ, Wilson LA, Behling C, Kleiner DE, et al
    Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
    Gastroenterology. 2023;165:463-472.
    PubMed     Abstract available
    
    
    
59. PENG Z, Li S, Pi R
    A Giant Cystic Liver Mass in an Elderly Man.
    Gastroenterology. 2023;165:e5-e7.
    PubMed    
    
    
    July 2023
60. REDDY KR, McLerran D, Marsh T, Parikh N, et al
    Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: the Multi-center Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
    Gastroenterology. 2023 Jul 8:S0016-5085(23)04765.
    PubMed     Abstract available
    
    
    June 2023
61. THIELE M, Suvitaival T, Trost K, Kim M, et al
    Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis.
    Gastroenterology. 2023;164:1248-1260.
    PubMed     Abstract available
    
    
    May 2023
62. FARIAS AQ, Vilalta AC, Zitelli PM, Pereira G, et al
    Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.
    Gastroenterology. 2023 May 30:S0016-5085(23)00806.
    PubMed     Abstract available
    
    
    April 2023
63. HAN H, Ge X, Babu Komakula SS, Desert R, et al
    MACROPHAGE-DERIVED OSTEOPONTIN (SPP1) PROTECTS FROM NON-ALCOHOLIC STEATOHEPATITIS.
    Gastroenterology. 2023 Apr 5:S0016-5085(23)00581.
    PubMed     Abstract available
    
    
    March 2023
64. LIU R, Dai Z, Zhu C
    A Rare Cause of Liver Fibrosis in an Adolescent Woman.
    Gastroenterology. 2023;164:340-343.
    PubMed    
    
    
    February 2023
65. TOH MR, Wong Yi Ting E, Wong Hei S, Ng Wei Tian A, et al
    Global epidemiology and genetics of hepatocellular carcinoma.
    Gastroenterology. 2023 Feb 2:S0016-5085(23)00105.
    PubMed     Abstract available
    
    
    November 2022
66. WANG Z, Tai Y, Wu H
    A rare cause of abdominal pain after transjugular intrahepatic portosystemic shunt.
    Gastroenterology. 2022 Nov 10. pii: S0016-5085(22)01258.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum